These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24863086)

  • 21. The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
    Sabuncu T; Ucar E; Birden F; Yasar O
    Diabetes Nutr Metab; 2004 Apr; 17(2):103-7. PubMed ID: 15244102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
    Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weight loss in obese African American and Caucasian adolescents: secondary analysis of a randomized clinical trial of behavioral therapy plus sibutramine.
    Budd GM; Hayman LL; Crump E; Pollydore C; Hawley KD; Cronquist JL; Berkowitz RI
    J Cardiovasc Nurs; 2007; 22(4):288-96. PubMed ID: 17589281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
    Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H; Meier M; Wendland G; Kurscheid T; Lauterbach K; ;
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes.
    Hung YJ; Chen YC; Pei D; Kuo SW; Hsieh CH; Wu LY; He CT; Lee CH; Fan SC; Sheu WH
    Diabet Med; 2005 Aug; 22(8):1024-30. PubMed ID: 16026368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
    Tong NW; Ran XW; Li QF; Tang BD; Li R; Yang FY; Liu YP; Li XJ
    Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):659-63. PubMed ID: 16202254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes.
    Kaukua JK; Pekkarinen TA; Rissanen AM
    Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.
    Tambascia MA; Geloneze B; Repetto EM; Geloneze SR; Picolo M; Magro DO
    Diabetes Obes Metab; 2003 Sep; 5(5):338-44. PubMed ID: 12940872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
    Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
    Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG; Goulder MA;
    J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
    Zannad F; Gille B; Grentzinger A; Bruntz JF; Hammadi M; Boivin JM; Hanotin C; Igau B; Drouin P
    Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.
    Hansen D; Astrup A; Toubro S; Finer N; Kopelman P; Hilsted J; Rössner S; Saris W; Van Gaal L; James W; Goulder M;
    Int J Obes Relat Metab Disord; 2001 Apr; 25(4):496-501. PubMed ID: 11319653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.